PlaqueTec Ltd

Opening a new frontier in the fight against #atherosclerosis

[PlaqueTec Ltd @PlaqueTec_UK]

PlaqueTec is investigating the biology at the site of disease to uncover patient-specific mechanisms of atherosclerosis and identify new, more precise targets for drug development.

Learn more: https://t.co/ALgW3LY2zv

[PlaqueTec Ltd @PlaqueTec_UK]

Today, our CSO, Dr Diane Proudfoot, is at the British Atherosclerosis Society Annual Meeting, joining conversations around inflammation, cardiovascular risk and new therapeutic opportunities.

[PlaqueTec Ltd @PlaqueTec_UK]

Our latest #MeetTheTeam interview features our CSO, Dr Diane Proudfoot, who talks about her career in cardiovascular research and why she was drawn to PlaqueTec’s approach to understanding atherosclerotic #cardiovasculardisease.

Read more: https://t.co/3Ryv3zvJOW

[PlaqueTec Ltd @PlaqueTec_UK]

These data are helping us to understand the mechanisms of different coronary artery disease endotypes.

The symposium will provide an opportunity to share insights with leading experts on the latest spectral technologies and analysis methods.

More here: https://t.co/1TOdz42qNz

[PlaqueTec Ltd @PlaqueTec_UK]

We're looking forward to the @BabrahamInst's Spectral Flow Cytometry Symposium.

Flow cytometry allows us to immunophenotype cells from participants' peripheral & coronary artery blood collected in our BIOPATTERN trial to see which cell types are enriched at the site of disease.

[PlaqueTec Ltd @PlaqueTec_UK]

As we look to develop precision medicines to transform outcomes for patients with coronary artery disease, multi-omic analysis will allow us to measure intracoronary gradients of thousands of biomolecules to identify new drivers of disease.

Find out more: https://t.co/JgDLfy8VM8

[PlaqueTec Ltd @PlaqueTec_UK]

Today, our CSO, Dr Diane Proudfoot is presenting at the @smcl_ngs MakeFest Facility Day, spotlighting PlaqueTec's Liquid Biopsy System™, used in the BIOPATTERN trial to collect blood samples containing biomolecules localising at or being released by coronary plaque.

[PlaqueTec Ltd @PlaqueTec_UK]

@BiotechTV Our recent $5M financing round is supporting our BIOPATTERN trial and the continued development of our proprietary cardiovascular data lake, BioCarta, a growing repository of unique intracoronary proteomic and clinical data.

Watch the full interview: https://t.co/xfpHDYhnIe

[PlaqueTec Ltd @PlaqueTec_UK]

🎥 Simon Williams, General Manager at PlaqueTec speaks to @BiotechTV, highlighting the aims of our BIOPATTERN trial to identify distinct disease endotypes & novel therapeutic targets for coronary artery disease, stressing that patients are faced with limited treatment options.

[BiotechTV @BiotechTV]

𝐅𝐫𝐨𝐦 𝐂𝐚𝐦𝐛𝐫𝐢𝐝𝐠𝐞, 𝐔𝐊: PlaqueTec Ltd.'s has a unique liquid biopsy system and multi omic analysis approach that aims to profile the underlying biology of atherosclerosis.

Full video: https://t.co/Y1a7HLweOU

[Babraham Research Campus @BabrahamUK]

Congratulations to Campus-based @PlaqueTec_UK on closing a $5m financing round which will support development of its cardiovascular disease database to inform patient stratification and therapeutic development programmes.
Full story https://t.co/qyXUnHIco6

[PlaqueTec Ltd @PlaqueTec_UK]

It was great to attend @o2hgroup's ChaiTime Discovery Club last week, which gathered medicinal chemists and drug discovery leaders to discuss emerging therapeutic areas and approaches.

Thank you to the o2h team for hosting a thought provoking and engaging event!

[PlaqueTec Ltd @PlaqueTec_UK]

This week, we announced a £5M financing round to support development of BioCarta, a growing repository of unique site-of-disease data to inform patient stratification and therapeutic development programmes for cardiovascular diseases.

More here: https://t.co/sPt79dtsDX

[PlaqueTec Ltd @PlaqueTec_UK]

Last night, we attended @businessweekly's networking evening to celebrate its Killer50 and Ones2Watch Life Sciences initiative, which spotlights the top 50 life sciences businesses and future cohort of potential game changers shaping the industry across Cambridge.

[PlaqueTec Ltd @PlaqueTec_UK]

📢 PlaqueTec raises $5M to support development of #cardiovasculardisease database.

The oversubscribed financing round will enable expansion of our cardiovascular data lake, BioCarta, providing a novel strategy to inform targeted therapeutic interventions: https://t.co/j6fpfZlkRA

[PlaqueTec Ltd @PlaqueTec_UK]

With additional expert-led talks, the agenda will also explore how other researchers are integrating Olink Reveal into their proteomics workflows to transform health research.

To find out more, or to register, visit: https://t.co/uK0F1KLzga

[PlaqueTec Ltd @PlaqueTec_UK]

This week, our CSO, Diane Proudfoot, is presenting at a seminar exploring cutting-edge proteomics in biomarker research.

Diane will discuss how we're using Olink® Reveal to detect spatial differences in protein levels at the surface of human coronary atherosclerotic plaques.

[PlaqueTec Ltd @PlaqueTec_UK]

We interviewed Stephen Chetwynd, Research Scientist, for the first blog in our Meet the Team series to learn more about the journey that led him to join PlaqueTec and to highlight his role in our ongoing BIOPATTERN trial.

Read more: https://t.co/DQDLjojTzq

[PlaqueTec Ltd @PlaqueTec_UK]

At PlaqueTec, we're characterising the inflammatory environment adjacent to coronary lesions using intracoronary sampling combined with omics technologies & cell phenotyping to uncover biomarker patterns that can inform precision medicines.

Learn more: https://t.co/xVYwo6wszH

[PlaqueTec Ltd @PlaqueTec_UK]

In a recent article published in @DDWJournal, PlaqueTec General Manager Dr Simon Williams highlights why precision medicine is expected to be an important trend in 2026.

Read more here: https://t.co/7wsX01aN8b

[PlaqueTec Ltd @PlaqueTec_UK]

@todaysclinical Site-of-disease blood sampling is taking precision profiling to the next level, supporting the identification of biomolecules contributing to individuals' disease to guide the use of #precisionmedicines.

Read more here: https://t.co/wbWFbk6EvN

[PlaqueTec Ltd @PlaqueTec_UK]

In an article published in @todaysclinical, Dr. Simon Williams, General Manager at PlaqueTec explores approaches to better characterise, risk stratify and treat individual patients with coronary artery disease.